Minerva Neurosciences Q3 2026 Earnings Date & Estimates

Minerva Neurosciences (NASDAQ:NERV). is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. The company’s research activities have centered on conditions including schizophrenia, major depressive disorder and other neuropsychiatric diseases with significant unmet medical needs.

Minerva’s lead investigational product has been roluperidone, formerly known as MIN-101, an orally administered compound studied as a potential treatment for negative symptoms of schizophrenia. The company has also been involved in the development of other central nervous system drug candidates, including treatments designed to influence serotonin, sigma and orexin receptor pathways.

Founded in 2007 and headquartered in Waltham, Massachusetts, Minerva has conducted clinical development activities in the United States and Europe. Its programs have primarily been advanced through clinical trials and collaborations with pharmaceutical companies and research organizations. As a development-stage biotechnology company, Minerva’s operations and product portfolio have historically focused on advancing investigational therapies rather than marketing an established commercial product line.